

World Journal of Hematology  
Editor-in-Chief  
Dr. Lian-Sheng Ma,  
President and Company Editor-in-Chief

May 10, 2013

Dear Dr. Lian-Sheng Ma:

Attached please find our revised manuscript (NO.2744—Review), which is an invited contribution, entitled “**Management of adult Langerhans cell histiocytosis based on the characteristic clinical features,**” which, we would like to be published in World Journal of Hematology as **Case Report**.

We have revised the manuscript in response to the criticisms and following the suggestions by the reviewer, as well as the editorial instructions, as follows:

Zip code, author contribution, core tip has been included. Tables have been inserted in the text. Figures have been arranged following the suggestions. Citations have been revised. In references, PMID numbers have been cited. Copyright assignment form has been prepared with signatures of all authors.

In response to Reviewers

Comment 1: if the authors would be bold enough in the Discussion to describe what treatment approach they will do for resected biopsy (no evidence of disease), but still minimal disease and systemic involvement. Also, what systemic chemotherapy would they suggest to do first. In our institution, 2 CDA has become the standard for systemic therapy for diffuse disease of LCH.

We have responded as follows:

In practice, for an adult case of LCH with persistent minimal disease and systemic involvement, we prefer once a month or twice a month treatment, like Special C regimen of JLSG.<sup>11</sup> Although we recognize that 2CDA is highly effective and could be useful in adult LCH, it is often difficult persuading the patients to stay in the hospital for the 5-day continuous treatment. If subcutaneous 2CDA is available at the outpatient care, this agent could be more employed in the treatment of adult LCH.

Comment 2: Please review the grammar. There are sentences and words repeated twice in the manuscript.

We have corrected redundant sentences and a number of minor grammatical errors. In addition we have corrected the errors previously escaped our notice. The corrected parts have been marked with yellow color.

I, as a corresponding author, hope that our manuscript has been sufficiently revised for publication.

We look forward to having your comments and criticisms.

Sincerely yours,

Shinsaku Imashuku, MD

my ID(01553776)